While it has been known for over two decades that anti-cancer drugs cannot penetrate deep into collagen-rich tumors (e.g., pancreatic cancers) and, more significantly, that depletion of collagen fibers can improve drug delivery, only recently TGFβ has become a target to reduce tumor fibrosis and thus, increase intratumoral drug concentration and treatment efficacy. Here, TGFB1 is linked to cancer.